Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 3, 2012, Pages 394-400

  Shiga, Yuhei ^a,b,c,d   Miura, Shin Ichiro ^a   Mitsutake, Ryoko ^a   Norimatsu, Kenji ^a   Nagata, Itsuki ^a,e   Arimura, Tadaaki ^a,e   Shimizu, Tomohiko ^a,e   Morii, Joji ^a,e   Kuwano, Takashi ^a   Uehara, Yoshinari ^a   Inoue, Asao ^b   Shirotani, Tetsuro ^c   Fujisawa, Kazuaki ^d   Matsunaga, Eiyu ^e   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

^c Shirotani Hospital   (Japan)

^d Fujisawa Clinic   (Japan)

^e Matsunaga Hospital   (Japan)

Author keywords

angiotensin II type 1 receptor blocker; Blood pressure; hemoglobin A1c; hydrochlorothiazide; potassium; uric acid

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; MICOMBI BP; UNCLASSIFIED DRUG;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; POTASSIUM BLOOD LEVEL; SIDE EFFECT; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 84865640109     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312439493     Document Type: Article

References (10)

1. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009 ; 32: 3-107
2. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 2007 ; 25: 1105-1187 (Pubitemid 46924065)
3. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005 ; 366: 895-906 (Pubitemid 41265663)
4. Kato J, Eto T. Diuretics in the LIFE study. Lancet. 2004 ; 364: 413
5. Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007 ; 6: 28
6. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226 (Pubitemid 44885684)
7. Bakris G, Burgess E, Weir M, Davidal G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 ; 74: 364-369 (Pubitemid 352002795)
8. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008 ; 21: 1157-1162
9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004 ; 43: 993-1002 (Pubitemid 38579904)
10. Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther. 2011 ;: